Skip to main content
WAVERLEY PHARMA INC. logo

WAVERLEY PHARMA INC. — Investor Relations & Filings

Ticker · WAVE ISIN · CA94357L1058 LEI · 254900VT8CXPPV1G5Q51 TSXV Manufacturing
Open in API
Filings indexed 110 across all filing types
Latest filing 2023-08-02 Regulatory Filings
Country CA Canada
Listing TSXV WAVE

About WAVERLEY PHARMA INC.

https://www.waverleypharma.com/

Waverley Pharma Inc. is a specialty biopharmaceutical company engaged in the research, development, and commercialization of safe, effective, and affordable therapeutics. The company primarily focuses on oncology, developing treatments such as poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer. Waverley Pharma commercializes its pharmaceutical products in markets including the United Kingdom, evidenced by successful tenders for drugs like Capecitabine with NHS Scotland. Furthermore, the company operates a retail pharmacy in the United States, integrating pharmaceutical innovation with direct patient service operations.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a business update announcement from Waverley Pharma Inc. It discusses the company's strategic shift and market conditions but does not contain financial statements, detailed financial analysis, or regulatory filings. It is not an earnings release, annual report, or interim report. It is a general corporate update about business strategy and market environment. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories.
2023-08-02 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 95% confidence The document is a notification to Canadian Securities Regulatory Authorities about an upcoming Annual and Special Meeting of Security Holders for Waverley Pharma Inc. It provides details such as meeting type, record dates, meeting date, location, and proxy material handling. The document does not contain financial data, management discussion, voting results, or any report content. It is an announcement related to a shareholder meeting, specifically providing logistical details rather than the meeting materials or results. Given the content and length (1025 characters), it is not a full report or proxy statement but rather a regulatory notification about the meeting. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-13 English
News release - English.pdf
Capital/Financing Update Classification · 85% confidence The document is a business update press release from Waverley Pharma providing information on its oncology products, market conditions, and strategic considerations. It does not contain financial statements, detailed financial analysis, or regulatory filings. It is not an earnings release, annual or interim report, nor a regulatory filing or management discussion. The content is a general business update aimed at informing investors and the public about current business status and outlook. Therefore, it fits best under the category of Capital/Financing Update (CAP) as it relates to business strategy and market conditions affecting the company's products and financial prospects.
2023-03-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Waverley Pharma providing an update on its PARP-1 inhibitor program, describing the status of its pre-clinical development and the company's focus. It includes forward-looking statements and general company information but does not contain any financial statements, regulatory filings, or detailed financial data. It is an update on a specific program rather than a financial report, management discussion, or regulatory filing. The document is not an announcement of a report publication, nor is it a certification or legal proceeding. It is a corporate update on a product development program, which fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-01-11 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management Discussion and Analysis' (MD&A) for Waverley Pharma Inc. for the three and nine months ended September 30, 2022. It includes detailed financial performance analysis, operational overview, forward-looking statements, and financial results for the interim period. The presence of actual financial data and analysis for a period shorter than a full fiscal year (quarterly and nine months) confirms this is an interim/quarterly report. The document is 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-11-24 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification statement by the CEO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2022. It is a Form 52-109FV2 Certification of Interim Filings for a venture issuer. The document does not contain the actual interim financial statements or substantive financial data but is an officer certification related to the interim filings. According to the Certification Rule, such certifications should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR). The document length is short (3011 characters), and it is clearly a certification letter, not the full interim report.
2022-11-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.